These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29183632)

  • 21. [The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].
    Kashiwada T; Azuma A
    Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):970-6. PubMed ID: 30168687
    [No Abstract]   [Full Text] [Related]  

  • 22. Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.
    Kaner RJ; Bajwa EK; El-Amine M; Gorina E; Gupta R; Lazarus HM; Luckhardt TR; Mouded M; Posada K; Richeldi L; Stauffer J; Tutuncu A; Martinez FJ
    Am J Respir Crit Care Med; 2019 Jul; 200(2):133-139. PubMed ID: 30985215
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
    Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
    BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
    Selvaggio AS; Noble PW
    Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is pirfenidone effective for idiopathic pulmonary fibrosis?
    Jeldres A; Labarca G
    Medwave; 2017 Jan; 17(Suppl1):e6843. PubMed ID: 28112713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
    Iwata T; Yoshida S; Fujiwara T; Wada H; Nakajima T; Suzuki H; Yoshino I
    Ann Thorac Surg; 2016 Dec; 102(6):1905-1910. PubMed ID: 27546601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2.
    Guler SA; Lindell KO; Swigris J; Ryerson CJ
    Am J Respir Crit Care Med; 2021 Feb; 203(3):P7-P8. PubMed ID: 33522880
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
    Hayton C; Chaudhuri N
    Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pirfenidone for idiopathic pulmonary fibrosis.
    Bouros D
    Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
    [No Abstract]   [Full Text] [Related]  

  • 32. New treatments in idiopathic pulmonary fibrosis.
    Strâmbu I
    Pneumologia; 2016; 65(3):127-32. PubMed ID: 29542881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
    King CS; Nathan SD
    Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
    [No Abstract]   [Full Text] [Related]  

  • 34. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.
    Raghu G
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
    Brown KK
    Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
    [No Abstract]   [Full Text] [Related]  

  • 36. [Two new drugs for the treatment of idiopathic lung fibrosis: A new therapeutic era!].
    Crestani B
    Rev Med Interne; 2015 Nov; 36(11):719-21. PubMed ID: 26065328
    [No Abstract]   [Full Text] [Related]  

  • 37. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment.
    Martinez FJ; Flaherty KR
    Chest; 2017 May; 151(5):1173-1174. PubMed ID: 28483105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Approach to Adult Fibrotic Lung Diseases.
    Adegunsoye A; Strek ME
    Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time].
    Einecke D
    MMW Fortschr Med; 2015 Feb; 157(2):24-5. PubMed ID: 25743506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.